A Phase 1 interventional study of Islatravir (ISL) and Lamivudine (3TC) in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During period 1, participants receive a single dose of islatravir (ISL). During Period 2, participants receive multiple once-daily doses of lamivudine (3TC) for 27 days, and a single dose of ISL co-administered with 3TC on day 6.
Drug: Islatravir (ISL) · Drug: Lamivudine (3TC)
Oral administration of a single dose in period 1 and period 2
Also known as: MK-8591, ISL
Oral administration of multiple daily doses for 27 days
Also known as: 3TC
Peripheral blood mononuclear cell (PBMC) Concentration at 168 hours (C168) of islatravir-triphosphate (ISL-TP )
Blood samples will be collected to determine the C168 of ISL-TP
Time frame: Predose and at designated timepoints up to 168 hours post dose
PBMC Concentration at 24 Hours (C24) of ISL-TP
Blood samples will be collected to determine the C24 of ISL-TP
Time frame: Predose and at designated timepoints up to 24 hours post dose
PBMC Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of ISL-TP
Blood samples will be collected to determine the AUC0-inf of ISL-TP
Time frame: Predose and at designated timepoints up to 840 hours post dose
PBMC Area Under the Concentration-time Curve to Time of Last Measurable Concentration (AUClast) of ISL-TP
Blood samples will be collected to determine the AUClast of ISL-TP
Time frame: Predose and at designated time points up to 840 hours post dose
PBMC Maximum Concentration (Cmax) of ISL-TP
Blood samples will be collected to determine the Cmax of ISL-TP
Time frame: Predose and at designated time points up to 840 hours post dose
PBMC Time to Maximum Concentration (Tmax) of ISL-TP
Blood samples will be collected to determine the Tmax of ISL-TP
Time frame: Predose and at designated time points up to 840 hours post dose
PBMC Apparent Terminal Half-life (t1/2) of ISL-TP
Blood samples will be collected to determine the t1/2 of ISL-TP
Time frame: Predose and at designated timepoints up to 840 hours post dose
Plasma C168 of ISL
Blood samples will be collected to determine the C168 of ISL
Time frame: Predose and at designated timepoints up to 168 hours post dose
Plasma Concentration at 24 Hours (C24) of ISL
Blood samples will be collected to determine the C24 of ISL
Time frame: Predose and at designated timepoints up to 24 hours post dose
Plasma AUC0-inf of ISL
Blood samples will be collected to determine the AUC0-inf of ISL
Time frame: Predose and at designated timepoints up to 168 hours post dose
Plasma AUClast of ISL
Blood samples will be collected to determine the AUClast of ISL
Time frame: Predose and at designated timepoints up to 168 hours post dose
Plasma Cmax of ISL
Blood samples will be collected to determine the Cmax of ISL
Time frame: Predose and at designated timepoints up to 168 hours post dose
Plasma Tmax of ISL
Blood samples will be collected to determine the Tmax of ISL-TP
Time frame: Predose and at designated timepoints up to 168 hours post dose
Plasma t1/2 of ISL
Blood samples will be collected to determine the t1/2 of ISL
Time frame: Predose and at designated timepoints up to 168 hours post dose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 16 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported
Time frame: Up to approximately 10 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2024 to primary completion in Jul 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Islatravir · Lamivudine